Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.87 [0.77, 0.97] | | < 1 | | 61% | 7 studies (7/-) | 99.2 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.62 [0.51, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
PFS (extension) | 0.60 [0.48, 0.74] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 1.08 [0.80, 1.45] | | < 1 | | 95% | 7 studies (7/-) | 30.7 % | some concern | not evaluable | moderate | important | - |
DCR | 0.77 [0.31, 1.90] | | > 1 | | 92% | 3 studies (3/-) | 28.6 % | some concern | not evaluable | moderate | non important | - |
objective responses (ORR) | 0.98 [0.54, 1.76] | | > 1 | | 90% | 7 studies (7/-) | 47.2 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 1.01 [0.51, 2.00] | | < 1 | | 63% | 4 studies (4/-) | 49.2 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) | 0.58 [0.18, 1.81] | | < 1 | | 97% | 4 studies (4/-) | 82.6 % | low | not evaluable | high | non important | - |
AE leading to death (grade 5) | 0.86 [0.57, 1.30] | | < 1 | | 0% | 4 studies (4/-) | 75.8 % | low | not evaluable | high | non important | - |
AE leading to treatment discontinuation (any grade) | 0.61 [0.24, 1.56] | | < 1 | | 92% | 4 studies (4/-) | 85.0 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 0.69 [0.29, 1.66] | | < 1 | | 0% | 1 study (1/-) | 79.5 % | NA | not evaluable | | non important | - |
SAE (any grade) | 0.97 [0.59, 1.60] | | < 1 | | 71% | 2 studies (2/-) | 54.1 % | some concern | not evaluable | moderate | non important | - |
SAE (grade 3-4) | 0.92 [0.61, 1.40] | | < 1 | | 0% | 1 study (1/-) | 64.6 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 1.52 [0.84, 2.76] | | < 1 | | 71% | 3 studies (3/-) | 8.5 % | some concern | not evaluable | moderate | non important | - |
STRAE (grade 3-4) | 1.85 [1.39, 2.48] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 0.58 [0.24, 1.38] | | < 1 | | 96% | 7 studies (7/-) | 89.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.62 [0.22, 1.75] | | < 1 | | 97% | 5 studies (5/-) | 81.8 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.58 [0.53, 4.68] | | < 1 | | 0% | 5 studies (5/-) | 20.4 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 0.76 [0.30, 1.93] | | < 1 | | 91% | 5 studies (5/-) | 71.9 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 1.49 [0.51, 4.32] | | < 1 | | 56% | 2 studies (2/-) | 23.4 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 0.50 [0.08, 3.03] | | < 1 | | 0% | 4 studies (4/-) | 77.5 % | some concern | not evaluable | moderate | non important | - |
Anaemia TRAE (grade 3-4) | 0.46 [0.15, 1.40] | | < 1 | | 89% | 5 studies (5/-) | 91.4 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.48 [0.20, 1.14] | | < 1 | | 40% | 4 studies (4/-) | 95.1 % | some concern | not evaluable | moderate | non important | - |
Blood creatinine increased TRAE (grade 3-4) | 0.73 [0.09, 6.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 0.35 [0.04, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 82.1 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.61 [0.28, 1.37] | | < 1 | | 50% | 6 studies (6/-) | 88.2 % | some concern | not evaluable | moderate | non important | - |
Diabetes TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.67 [0.30, 1.49] | | < 1 | | 57% | 6 studies (6/-) | 83.7 % | some concern | not evaluable | moderate | non important | - |
Dizziness TRAE (grade 3-4) | 0.73 [0.09, 6.31] | | < 1 | | 0% | 2 studies (2/-) | 61.0 % | low | not evaluable | high | non important | - |
Dry skin TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
Dysgeusia TRAE (grade 3-4) | 0.97 [0.06, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
Endocrine disorders TRAE (grade 3-4) | 9.86 [0.54, 180.88] | | < 1 | | 0% | 1 study (1/-) | 6.4 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.72 [0.33, 1.56] | | < 1 | | 64% | 6 studies (6/-) | 80.0 % | some concern | serious | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.40] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 1.73 [1.04, 2.86] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 7.60 [0.40, 144.43] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 1.81 [0.97, 3.36] | | < 1 | | 0% | 1 study (1/-) | 3.0 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.68 [0.04, 10.84] | | < 1 | | 0% | 2 studies (2/-) | 60.8 % | some concern | not evaluable | moderate | non important | - |
Hypophysitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 4.31 [0.72, 25.71] | | < 1 | | 28% | 4 studies (4/-) | 5.5 % | some concern | not evaluable | moderate | non important | - |
Increase AST TRAE (grade 3-4) | 1.95 [0.85, 4.47] | | < 1 | | 0% | 3 studies (3/-) | 5.8 % | some concern | not evaluable | moderate | non important | - |
Increased ALT TRAE (grade 3-4) | 0.97 [0.40, 2.40] | | < 1 | | 0% | 3 studies (3/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
Increased lipase level TRAE (grade 3-4) | 1.74 [0.36, 8.39] | | < 1 | | 50% | 2 studies (2/-) | 24.5 % | some concern | not evaluable | moderate | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.95 [0.09, 10.52] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
Leucopenia TRAE (grade 3-4) | 2.43 [0.23, 25.98] | | < 1 | | 34% | 2 studies (2/-) | 23.2 % | low | not evaluable | high | non important | - |
Maculopapular rash TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.20 [0.01, 4.07] | | < 1 | | 77% | 2 studies (2/-) | 85.1 % | low | not evaluable | high | non important | - |
Nausea TRAE (grade 3-4) | 0.61 [0.28, 1.34] | | < 1 | | 46% | 6 studies (6/-) | 89.1 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 0.25 [0.08, 0.74] | | < 1 | | 88% | 5 studies (5/-) | 99.4 % | some concern | serious | moderate | non important | - |
Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 1.04 [0.32, 3.44] | | < 1 | | 60% | 3 studies (3/-) | 47.2 % | some concern | not evaluable | moderate | non important | - |
Pancreatitis TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 1.13 [0.44, 2.87] | | < 1 | | 25% | 4 studies (4/-) | 39.9 % | some concern | not evaluable | moderate | non important | - |
Peripheral sensory neuropathy TRAE (grade 3-4) | 1.33 [0.50, 3.53] | | < 1 | | 10% | 2 studies (2/-) | 28.5 % | some concern | not evaluable | moderate | non important | - |
Pneumonitis TRAE (grade 3-4) | 2.04 [0.21, 20.20] | | < 1 | | 0% | 2 studies (2/-) | 27.2 % | some concern | not evaluable | moderate | non important | - |
Pruritus TRAE (grade 3-4) | 0.77 [0.08, 7.42] | | < 1 | | 0% | 3 studies (3/-) | 58.9 % | low | not evaluable | high | non important | - |
Pyrexia TRAE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 1.04 [0.12, 8.94] | | < 1 | | 0% | 3 studies (3/-) | 48.5 % | low | not evaluable | high | non important | - |
Renal and urinary disorders TRAE (grade 3-4) | 5.92 [0.71, 49.31] | | < 1 | | 0% | 1 study (1/-) | 5.1 % | NA | not evaluable | | non important | - |
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 13.96 [1.83, 106.45] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
Severe skin reaction TRAE (grade 3-4) | 1.88 [0.06, 56.28] | | < 1 | | 0% | 1 study (1/-) | 36.0 % | NA | not evaluable | | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 4.36 [1.79, 10.66] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
Stomatitis TRAE (grade 3-4) | 0.34 [0.02, 6.97] | | < 1 | | 77% | 2 studies (2/-) | 75.7 % | low | not evaluable | high | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 1.00 [0.38, 2.62] | | < 1 | | 46% | 3 studies (3/-) | 50.3 % | some concern | not evaluable | moderate | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.56 [0.26, 1.24] | | < 1 | | 41% | 4 studies (4/-) | 92.3 % | some concern | not evaluable | moderate | non important | - |
Weight decreased TRAE (grade 3-4) | 0.44 [0.06, 3.49] | | < 1 | | 36% | 3 studies (3/-) | 77.9 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
Abdominal pain AE (grade 3-4) | 1.14 [0.43, 3.04] | | < 1 | | 0% | 1 study (1/-) | 39.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.97 [0.54, 1.75] | | < 1 | | 0% | 1 study (1/-) | 53.7 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 2.48 [0.54, 11.47] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.73 [0.12, 4.41] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.54 [0.20, 1.42] | | < 1 | | 0% | 1 study (1/-) | 89.5 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 1.96 [0.22, 17.71] | | < 1 | | 0% | 1 study (1/-) | 27.5 % | NA | not evaluable | | non important | - |
Dyspepsia AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.96 [0.09, 43.66] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.29 [0.07, 1.21] | | < 1 | | 0% | 1 study (1/-) | 95.5 % | NA | not evaluable | | non important | - |
Increase AST AE (grade 3-4) | 1.48 [0.47, 4.67] | | < 1 | | 0% | 1 study (1/-) | 25.2 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 1.31 [0.34, 5.00] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.24 [0.02, 2.68] | | < 1 | | 0% | 1 study (1/-) | 87.4 % | NA | not evaluable | | non important | - |
Peripheral oedema AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 1.47 [0.15, 14.22] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.65 [0.14, 2.92] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |